Aims-To establish the prevalence of c-erbB-2 protein expression in a surgical series of Barrett's adenocarcinomas; and to correlate this expression with clinicopathological data and prognosis.
Methods-Sixty six surgical specimens of
Barrett's adenocarcinomas were included in this retrospective study. Blocks of the tumour and of non-dysplastic Barrett's mucosa were stained with a polyclonal antibody specific for the intracytoplasmic domain of the c-erbB-2 protein. Results-Seven of 66 tumours showed membrane staining for the c-erbB-2 protein. The non-dysplastic Barrett's mucosa was negative in all cases. There was no difference between c-erbB-2 positive and negative tumours with regard to mean age, sex ratio, percentage of alcohol misusers, percentage of smokers, tumour differentiation, depth of invasion, lymph node response, and proliferative activity, assessed by the percentage of tumour cells positive with the MIB-1 antibody directed against the Ki-67 antigen. All c-erb B2 positive tumours were of Lauren's intestinal type compared with negative c-erbB-2 tumours. Patients with c-erbB-2 positive tumours had a significantly poorer prognosis than patients with negative tumours. Conclusions-The prevalence of Barrett's adenocarcinomas expressing c-erbB-2 found in this study (11%) was similar to that observed in published series of gastric adenocarcinomas. c-erbB-2 protein expression could be an important prognostic indicator in Barrett's adenocarcinoma. (7 Clin Pathol 1994; 47:23-26) c-erbB-2 is a proto-oncogene that codes for a 185 kilodalton glycoprotein, with high homology with the epidermal growth factor receptor.' The c-erbB-2 gene product is thought to be activated by specific ligand(s), resulting in the stimulation of cytoplasmic tyrosine kinase activity and causing signal transduction in the cell.23 Amplification of the c-erbB-2 gene occurs in various tumours, including adenocarcinomas of the stomach.4 5 The immunohistochemical staining of the membranes of tumour cells using specific antibodies directed against c-erbB-2 protein, is a reliable marker of c-erbB-2 gene amplification.6 This staining has been reported as a prognostic indicator in some tumoursnotably in adenocarcinoma of the breast.7 Its prognostic importance, however, in gastric adenocarcinoma is debatable, and no data are available regarding Barrett's adenocarcinoma. 8 fixed tumours, the MIB-1 labelling index was Discussion similar in the four c-erbB-2 positive cases and In this study we have shown, by immunohisin the 42 c-erbB-2 negative cases (table) . tochemistry, an increased c-erbB-2 protein Moreover, when considering only c-erbB-2 expression in 11% (7/66) of Barrett's adenopositive cases, the MIB-1 labelling index was carcinomas. In two published studies of similar in c-erbB-2 positive and negative areas c-erbB-2 protein expression in adenocarcino-(data not shown). mas of the oesophagus 11 of 15 (73%) and Tumours with positive c-erbB2 staining had six of 10 (60%) adenocarcinomas overexa poorer outcome at one (29%), two (14%), pressed the c-erbB-2 protein, a figure much and five years (0%), compared, respectively, higher than ours.'920 In the present series with 63%, 40%, and 33% in the c-erbB-2 dysplastic (n = 30) and non-dysplastic (n = negative group (p < 0-05) (fig 3) . 66) Barrett's mucosa around the tumour were c-erbB-2 negative. This result compares well with the features observed in gastric mucosa around gastric cancers4 9 11 The prognostic value of c-erbB-2 protein overexpression has been diversely appreciated in gastric adenocarcinoma. Jain et a18 have suggested that c-erbB-2 overexpression was associated with better prognosis, while in a larger study, Yonemura et al found that overexpression was associated with a worse prognosis,9 as in breast adenocarcinoma.7 Recently, two groups did not find any prognostic value for c-erbB-2 protein overexpression" 27; on the other hand, in a study of 220 early gastric cancers Yonemura et al found that positive c-erbB-2 staining was associated with lymph node metastasis.28 A complete confirmation of prognostic value will require a greater number of gastric cancer cases to be studied. In this study the overexpression of c-erbB-2 protein by Barrett's adenocarcinoma seemed to correlate with lower survival. c-erbB-2 positivity, moreover, was related neither to the depth of tumour invasion, nor to the presence of lymph node metastases, two prognostic markers of Barrett's adenocarcinoma,12 suggesting that it may have an independent prognostic value. This independent prognostic value can only be demonstrated by multivariate analysis involving a large number of patients and avoiding confounding variables, such as later presentation of patients with c-erbB-2 positive tumours. Tumours which overexpress c-erbB-2 may be associated with a higher degree of proliferation than c-erbB-2 negative tumours. '9 This hypothesis has been verified in breast adenocarcinoma using flow cytometry. 30 
